These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
94 related articles for article (PubMed ID: 20070285)
21. Intranasal immunization with CpG oligodeoxynucleotides as an adjuvant dramatically increases IgA and protection against herpes simplex virus-2 in the genital tract. Gallichan WS; Woolstencroft RN; Guarasci T; McCluskie MJ; Davis HL; Rosenthal KL J Immunol; 2001 Mar; 166(5):3451-7. PubMed ID: 11207303 [TBL] [Abstract][Full Text] [Related]
22. Prolonged exposure to progesterone prevents induction of protective mucosal responses following intravaginal immunization with attenuated herpes simplex virus type 2. Gillgrass AE; Ashkar AA; Rosenthal KL; Kaushic C J Virol; 2003 Sep; 77(18):9845-51. PubMed ID: 12941893 [TBL] [Abstract][Full Text] [Related]
23. Analysis of herpes simplex virus-specific T cells in the murine female genital tract following genital infection with herpes simplex virus type 2. Milligan GN; Bernstein DI Virology; 1995 Oct; 212(2):481-9. PubMed ID: 7571418 [TBL] [Abstract][Full Text] [Related]
24. The mucosal adjuvant effect of alpha-galactosylceramide for induction of protective immunity to sexually transmitted viral infection. Lindqvist M; Persson J; Thörn K; Harandi AM J Immunol; 2009 May; 182(10):6435-43. PubMed ID: 19414797 [TBL] [Abstract][Full Text] [Related]
25. Estradiol regulates susceptibility following primary exposure to genital herpes simplex virus type 2, while progesterone induces inflammation. Gillgrass AE; Fernandez SA; Rosenthal KL; Kaushic C J Virol; 2005 Mar; 79(5):3107-16. PubMed ID: 15709030 [TBL] [Abstract][Full Text] [Related]
26. T-cell-mediated mechanisms involved in resolution of genital herpes simplex virus type 2 (HSV-2) infection of mice. Milligan GN; Dudley-McClain KL; Young CG; Chu CF J Reprod Immunol; 2004 Apr; 61(2):115-27. PubMed ID: 15063634 [TBL] [Abstract][Full Text] [Related]
27. Vaccine-induced serum immunoglobin contributes to protection from herpes simplex virus type 2 genital infection in the presence of immune T cells. Morrison LA; Zhu L; Thebeau LG J Virol; 2001 Feb; 75(3):1195-204. PubMed ID: 11152492 [TBL] [Abstract][Full Text] [Related]
28. Long-term immunity and protection against herpes simplex virus type 2 in the murine female genital tract after mucosal but not systemic immunization. Gallichan WS; Rosenthal KL J Infect Dis; 1998 May; 177(5):1155-61. PubMed ID: 9592997 [TBL] [Abstract][Full Text] [Related]
29. Comparison of different forms of herpes simplex replication-defective mutant viruses as vaccines in a mouse model of HSV-2 genital infection. Da Costa XJ; Morrison LA; Knipe DM Virology; 2001 Sep; 288(2):256-63. PubMed ID: 11601897 [TBL] [Abstract][Full Text] [Related]
30. Immune protection against HSV-2 in B-cell-deficient mice. Dudley KL; Bourne N; Milligan GN Virology; 2000 May; 270(2):454-63. PubMed ID: 10793004 [TBL] [Abstract][Full Text] [Related]
31. Delayed but effective induction of mucosal memory immune responses against genital HSV-2 in the absence of secondary lymphoid organs. Roth KL; Bhavanam S; Jiang H; Gillgrass A; Ho K; Ferreira VH; Kaushic C Mucosal Immunol; 2013 Jan; 6(1):56-68. PubMed ID: 22718264 [TBL] [Abstract][Full Text] [Related]
32. Herpes simplex virus (HSV) type 2 glycoprotein D subunit vaccines and protection against genital HSV-1 or HSV-2 disease in guinea pigs. Bourne N; Bravo FJ; Francotte M; Bernstein DI; Myers MG; Slaoui M; Stanberry LR J Infect Dis; 2003 Feb; 187(4):542-9. PubMed ID: 12599070 [TBL] [Abstract][Full Text] [Related]
33. CpG oligodeoxynucleotide augments HSV-2 glycoprotein D DNA vaccine efficacy to generate T helper 1 response and subsequent protection against primary genital herpes infection in mice. Tengvall S; Josefsson A; Holmgren J; Harandi AM J Reprod Immunol; 2005 Dec; 68(1-2):53-69. PubMed ID: 16229896 [TBL] [Abstract][Full Text] [Related]
34. Immunity to vaginal HSV-2 infection in immunoglobulin A knockout mice. Parr MB; Harriman GR; Parr EL Immunology; 1998 Oct; 95(2):208-13. PubMed ID: 9824477 [TBL] [Abstract][Full Text] [Related]
36. Effect of immunization with herpes simplex virus type-1 (HSV-1) glycoprotein D (gD) plus the immune enhancer GPI-0100 on infection with HSV-1 or HSV-2. Quenelle DC; Collins DJ; Marciani DJ; Kern ER Vaccine; 2006 Mar; 24(10):1515-22. PubMed ID: 16288820 [TBL] [Abstract][Full Text] [Related]
37. Construction and characterization of a replication-defective herpes simplex virus 2 ICP8 mutant strain and its use in immunization studies in a guinea pig model of genital disease. Da Costa XJ; Bourne N; Stanberry LR; Knipe DM Virology; 1997 May; 232(1):1-12. PubMed ID: 9185583 [TBL] [Abstract][Full Text] [Related]